EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics

Shuai Wang iD, Matan Uriel, Haiying Cheng iD

Journal of Clinical Medicine · 03.12.2024 · 13 (23) · 7371

DOI: 10.3390/jcm13237371 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.12.2024. Verfasst von Shuai Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is a leading cause of brain metastases (BMs), with 10–20% of patients with non-small cell lung cancer (NSCLC) presenting with BMs at diagnosis and 25–50% developing them over the course of their disease. Historically, BMs have posed significant therapeutic challenges, partly due to the blood brain barrier (BBB), which restricts drug penetration to the central nervous system. Consequently, BMs were initially managed with local treatments, including surgical resection, stereotactic radiosurgery, and whole brain radiation therapy. In recent years, however, systemic treatments for BMs have advanced significantly, particularly with the development of molecularly-targeted therapies and immunotherapies. The discovery of driver mutations and the development of novel tyrosine kinase inhibitors (TKIs) have yielded encouraging intracranial responses in NSCLC patients with actionable genetic alterations (e.g., EGFR, ALK, ROS1). Genomic profiling has also suggested genetic heterogeneity between BMs and primary sites. Immunotherapies, alone or in combination with other treatments, have demonstrated promising results in NSCLC with BMs, although most clinical trials have included only selected patients with asymptomatic or previously treated BMs. In this review, we discuss the molecular and immune characteristics of NSCLC with BMs, analyze intracranial efficacy findings from clinical trials, and explore treatment strategies for lung cancer patients with BMs.

Schlagwörter

Stichwörter der Autor:innen

brain metastasesimmunotherapylung cancertargeted therapy

Autor:innen und Institutionen

  • Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.

ORCID-Profile: Shuai Wang, Haiying Cheng

Zitieren

APA

Wang, S., Uriel, M., & Cheng, H. (2024). Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics. Journal of Clinical Medicine, 13(23), 7371. https://doi.org/10.3390/jcm13237371

Vancouver

Wang S, Uriel M, Cheng H. Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics. Journal of Clinical Medicine. 2024;13(23):7371. doi:10.3390/jcm13237371

BibTeX
@article{Wang2024,
  author = {Wang, Shuai and Uriel, Matan and Cheng, Haiying},
  title = {Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {23},
  pages = {7371},
  doi = {10.3390/jcm13237371}
}
Kostenlos starten →